Nuvectis Pharma Inc

Nuvectis Pharma Inc (NVCT) News & Events

$18.600

-0.324 (-1.74%)At close

NVCT News

NVCT Events

9/24 08:30

Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation

Nuvectis Pharma announced that NXP200 has been granted Breakthrough Therapy Designation, BTD, for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China's Center for Drug Evaluation, CDE. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We congratulate our partner Haisco for achieving this significant regulatory milestone, which is further testament to its tremendous strategic and operational capabilities. The CDE's granting of Breakthrough Therapy Designation underscores the compelling clinical activity observed to date with NXP200 in patients with recurrent or progressive BRAF V600-mutant high-grade glioma. In parallel, we continue to advance NXP200 toward a U.S. IND submission in the fourth quarter of 2026."

8/21 17:00

Nuvectis Pharma Files $200M Mixed Securities Shelf

Nuvectis Pharma files $200M mixed securities shelf

7/23 08:00

Nuvectis Pharma Receives Approval for Ciprocopan to Treat Paroxysmal Nocturnal Hemoglobinuria

Nuvectis Pharma announced that ciprocopan, a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China, or NMPA, for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria previously untreated with Complement inhibitors.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading